Novo Nordisk Unveils Strategy For Dominating Diabetes Market In China
This article was originally published in PharmAsia News
Novo Nordisk has carved out a dominant position in China's diabetic drug market despite launching only one oral hypoglycemic agent and insulin thanks to its 20-year presence in the country that allows the establishment of an extensive sales network. Its revenue is evenly split between key cities and periphery markets. The company's strategy is to actively conduct health education on diabetes in two areas, namely, mainstream patient education and physician training in communities. In addition, Novo Nordisk expects to make an official announcement this October about its plans to set up a plant in Tianjin that will supply products to China and more than 200 countries worldwide. (Click here for more - Chinese Language)
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.